RAPT Therapeutics Q2 net loss narrows to $17.6 mln, R&D expenses drop
RefinitivMeno di 1 minuto di lettura
Overview
RAPT Q2 net loss narrows to $17.6 mln from $27.7 mln last year
Research and development expenses drop; General and administrative expenses rise
Result Drivers
R&D EXPENSES - Decreased to $12.3 mln on reduced spending on zelnecirnon and tivumecirnon, offset by increased costs for RPT904 and early-stage programs
G&A EXPENSES - Increased to $7.2 mln primarily due to higher consulting and facilities costs
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Net Income | -$17.64 mln | ||
Q2 Basic EPS | -$0.65 | ||
Q2 Operating Expenses | $19.54 mln | ||
Q2 Operating Income | -$19.54 mln |
Press Release:
Accedi o crea un account gratuito per leggere queste notizie